The Pentagon has issued new clinical guidance mandating testosterone deficiency screening for US military personnel aged 30 and older, while explicitly prohibiting the use of the hormone for performance enhancement. The Defence Health Agency released the directive on 17 September 2026, establishing uniform screening and treatment protocols for active-duty and reserve male service members under a broader July directive.

What the Guidance Covers

The directive requires a structured symptom and risk-factor assessment as the first step. Blood testing follows only when that assessment is positive or a recognised risk factor is present. Service members under 30 may request screening voluntarily, but the mandate applies to those 30 and older.

A confirmed diagnosis requires consistently low testosterone levels alongside compatible symptoms — a low lab reading or symptoms alone are not sufficient. The protocol calls for two morning blood samples taken while fasting on separate days. Additional testing is provided for when symptoms persist despite readings within the normal range.

Performance Enhancement Explicitly Ruled Out

The clinical document draws a firm line between treating a diagnosed deficiency and prescribing testosterone to boost battlefield performance. 'Guidance premised on performance enhancement rather than on treatment of a diagnosed deficiency is not supportable on the current evidence,' the document states. This distinction is central to the guidance, distancing the initiative from any suggestion of hormone doping in the armed forces.

Symptoms, Overlap and Diagnosis Challenges

Recognised symptoms include reduced sexual desire, diminished energy, impaired concentration, reduced muscle mass, and depressed mood. The guidance cautions that these can closely overlap with conditions common in military life — including sleep deprivation, psychological stress, and inadequate calorie intake — complicating accurate diagnosis.

The document acknowledges that testosterone therapy has demonstrated benefits for sexual function, body composition, and bone mineral density, but states that evidence does not support its use for improving energy, vitality, physical function, or cognition.

Combat Readiness and Deployability

The Pentagon linked the initiative directly to combat readiness. 'The Department remains focused on building and maintaining a ready, lethal fighting force prepared to dominate the battlefield and achieve peace through strength,' the chief Pentagon spokesman said in a statement.

Personnel already stable on testosterone therapy should generally remain deployable without a waiver, depending on the formulation used. Providers are required to ensure sufficient medication for the deployment period plus an additional 90 days, or to document a resupply plan. Separate rules continue to govern specialised duty assignments.

Scale of the Issue and Personnel Rights

Military surveillance data cited in the guidance show that fewer than 1 per cent of male service members carried an active clinical diagnosis of testosterone deficiency annually between 2018 and 2025 — suggesting the screening programme could identify a substantial undiagnosed population. Notably, the accompanying patient information sheet makes clear that participation in treatment is voluntary. 'Declining evaluation or treatment carries no adverse personnel consequence,' it states, ensuring the policy does not become a coercive medical mandate.

The guidance is expected to reshape how military healthcare providers approach hormonal health assessments across hundreds of thousands of active and reserve personnel, with implementation now under way.